Advanced Enzyme Technologies Limited has announced robust financial results for the fourth quarter and the full fiscal year ended March 2026. The company reported a significant 22% year-on-year revenue growth in Q4, driven by strong performance across its key segments. With a focus on strategic expansion, internal accruals, and a debt-free status, the firm continues to solidify its global leadership in the specialty biotech, enzyme, and probiotic manufacturing sectors.
Financial Highlights for Q4 FY26
For the quarter ended March 2026, Advanced Enzyme Technologies achieved a consolidated revenue of ₹2,034 million, representing a 22% year-on-year increase compared to ₹1,672 million in the same period last year. The company’s profitability saw impressive gains, with EBITDA rising 39% to ₹632 million, and Profit After Tax (PAT) climbing by 69% to ₹453 million. The Earnings Per Share (EPS) for the quarter stood at ₹3.84, up from ₹2.37 in Q4 FY25.
Annual Performance Summary
On an annual basis, the company reported consolidated revenue of ₹7,458 million for FY26, a 17% growth over FY25. EBITDA for the year reached ₹2,291 million, reflecting an 18% increase, while PAT grew by 30% to ₹1,736 million. The annual EPS improved to ₹15.08 compared to ₹11.72 in the previous fiscal year, supported by a healthy 31% EBITDA margin.
Segmental and Geographical Growth
The Human Nutrition segment remained the primary revenue contributor, growing 24% in Q4 to ₹1,281 million, fueled by increased activities in the Pharma/API and Bio-catalysis sectors. The Animal Nutrition segment also delivered strong results with a 19% growth to ₹250 million. Geographically, domestic operations experienced significant momentum, with sales rising 51% to ₹1,061 million in Q4, while international sales remained steady.
Future Strategic Outlook
Looking ahead to 2026-27, the company is prioritizing its B2C strategy in India through the expansion of its nutraceutical brand, Wellfa. Additionally, the company continues to invest in Research & Development and biocatalysis for API manufacturers. With its commitment to a zero-debt business model and successful track record of four acquisitions in the last nine years, Advanced Enzyme Technologies is well-positioned to leverage strategic inorganic growth opportunities and further expand its global footprint.
Source: BSE
